Adagene Inc
ADAG1.945USD
+0.025+1.30%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
114.54MMarktkapitalisierung
--KGV TTM
mehr Informationen über Adagene Inc Unternehmen
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Unternehmensinformationen
BörsenkürzelADAG
Name des UnternehmensAdagene Inc
IPO-datumFeb 09, 2021
CEODr. Peter (Peizhi) Luo, Ph.D.
Anzahl der mitarbeiter138
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 09
Addresse4F, Building C14, No. 218, Xinghu Street
StadtSUZHOU
BörseNASDAQ Global Market Consolidated
LandChina
Postleitzahl- -
Telefon8651287773632
Websitehttps://www.adagene.com/
BörsenkürzelADAG
IPO-datumFeb 09, 2021
CEODr. Peter (Peizhi) Luo, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Umsatzaufteilung
FY2024
FY2023
FY2022
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
China (Mainland)
103.20K
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
Aktionäre
Aktionäre
Anteil
WuXi AppTec Co, Ltd.
8.45%
General Atlantic LLC
8.12%
Olive Tree Capital
7.57%
HSG Holding Ltd.
2.85%
Luo (Peter)
2.77%
Other
70.23%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
17.67%
Private Equity
8.12%
Venture Capital
7.57%
Individual Investor
2.77%
Corporation
1.93%
Investment Advisor/Hedge Fund
0.02%
Other
61.91%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
32
17.95M
38.09%
-2.89M
2025Q1
34
22.22M
47.17%
+1.25M
2024Q4
30
19.43M
43.91%
+6.91M
2024Q3
29
16.58M
37.45%
+3.51M
2024Q2
30
13.07M
29.54%
-384.35K
2024Q1
31
14.15M
32.04%
+4.42M
2023Q4
27
7.53M
17.08%
-3.44M
2023Q3
33
8.73M
19.93%
-2.62M
2023Q2
35
8.75M
19.96%
-2.76M
2023Q1
46
8.82M
20.14%
-5.30M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
WuXi AppTec Co, Ltd.
3.98M
8.45%
--
--
Mar 31, 2025
General Atlantic LLC
3.83M
8.12%
--
--
Mar 31, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Mar 31, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Fidelity International
749.45K
1.59%
-2.53M
-77.11%
Mar 31, 2025
Fidelity Management & Research Company LLC
473.95K
1.01%
-707.69K
-59.89%
Jun 30, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
